Journal
METHODS
Volume 101, Issue -, Pages 56-64Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymeth.2015.10.017
Keywords
Differentiation; Pancreas; Beta cells; Diabetes; Human embryonic stem cells (hESCs); Human induced pluripotent stem cells (hiPSCs)
Funding
- McEwen Centre for Regenerative Medicine
- Toronto General and Western Hospital Foundation
Ask authors/readers for more resources
Generation of pancreatic beta-cells from human pluripotent stem cells (hPSCs) has enormous importance in type I diabetes (T1D), as it is fundamental to a treatment strategy based on cellular therapeutics. Being able to generate beta-cells, as well as other mature pancreatic cells, from human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) will also enable the development of platforms that can be used for disease modeling and drug testing for a variety of pancreas-associated diseases, including cystic fibrosis. For this to occur, it is crucial to develop differentiation strategies that are robust and reproducible across cell lines and laboratories. In this article we describe two serum-free differentiation protocols designed to generate specific pancreatic lineages from hPSCs. Our approach employs a variety of cytokines and small molecules to mimic developmental pathways active during pancreatic organogenesis and allows for the in vitro generation of distinct pancreatic populations. The first protocol is designed to give rise to polyhormonal cells that have the potential to differentiate into glucagon-producing cells. The second protocol is geared to generate multipotent pancreatic progenitor cells, which harbor the potential to generate all pancreatic lineages including: monohormonal endocrine cells, acinar, and ductal cells. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available